Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal — report
The latest buyout buzz focuses on a small UK biotech spinout working on a new drug for women’s health.
Bloomberg is reporting this morning that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
